| |
All ACS
|
STEMI
|
NSTE-ACS
|
|---|
|
Unadjusted OR (95% CI)
|
p value
|
Adjusted OR (95% CI)
|
p value
|
Unadjusted OR (95% CI)
|
p value
|
Adjusted OR (95% CI)
|
p value
|
Unadjusted OR (95% CI)
|
p value
|
Adjusted OR (95% CI)
|
p value
|
|---|
|
The whole study population
|
|
All-cause deatha
|
2.49 (2.22–2.80)
|
< 0.001
|
2.04 (1.78–2.33)
|
< 0.001
|
2.45 (2.14–2.80)
|
< 0.001
|
2.07 (1.76–2.43)
|
< 0.001
|
2.76 (2.19–3.47)
|
< 0.001
|
1.93 (1.48–2.51)
|
< 0.001
|
|
MACCEb
|
1.98 (1.80–2.18)
|
< 0.001
|
1.54 (1.39–1.72)
|
< 0.001
|
2.03 (1.81–2.27)
|
< 0.001
|
1.66 (1.46–1.89)
|
< 0.001
|
1.92 (1.60–2.29)
|
< 0.001
|
1.30 (1.06–1.58)
|
0.010
|
|
Propensity score-matched population
|
|
All-cause death
|
2.08 (1.74–2.47)
|
< 0.0001
|
2.21 (1.83–2.66)
|
< 0.001
|
2.18 (1.77–2.69)
|
< 0.001
|
2.34 (1.87–2.92)
|
< 0.001
|
1.85 (1.34–2.54)
|
< 0.001
|
1.96 (1.39–2.77)
|
< 0.001
|
|
MACCE
|
1.55 (1.36–1.77)
|
< 0.001
|
1.58 (1.38–1.82)
|
< 0.001
|
1.65 (1.4–1.94)
|
< 0.001
|
1.73 (1.46–2.05)
|
< 0.001
|
1.35 (1.06–1.71)
|
0.015
|
1.31 (1.02–1.69)
|
0.033
|
- ACS acute coronary syndrome, STEMI ST-segment elevation myocardial infarction, NSTE-ACS non-ST-segment elevation acute coronary syndrome, MACCE major adverse cardiovascular and cerebrovascular events, OR odds ratio
- a After forward stepwise selection, the adjusted variables for all-cause death finally included age, sex, SBP, heart rate, heart failure history, cerebrovascular disease history, Killip class at admission, cardiac arrest at admission, eGFR, in-hospital treatment of statins, β-blockers, ACEIs/ARBs, PCI, fivefold elevated myocardial injury markers, type of ACS, and whether patients were transferred from another hospital before the current hospitalization
- b After forward stepwise selection, the adjusted variables for MACCE finally included age, sex, smoking, SBP, heart rate, heart failure history, renal failure history, cerebrovascular disease history, Killip class at admission, cardiac arrest at admission, eGFR, in-hospital treatment with dual anti-platelet therapy, statins, ACEIs/ARBs, PCI, fivefold elevated myocardial injury markers, type of ACS, and whether patients were transferred from another hospital before the current hospitalization
